D-tagatose dental caries research gives formulators two reasons to consider this rare sugar. It offers a noncariogenic sweetener option and shows potential against plaque bacteria. Yet the small human trials report mixed results. They do not establish that tagatose alone prevents new cavities. (Angarita-Davila et al., 2025b)
For procurement and regulatory teams, that distinction shapes the product brief. Start with sugar replacement. Then match each oral health claim to the formula, test results, and target market.
D-Tagatose as a Noncariogenic Sweetener
D-tagatose belongs to the monosaccharide family. Chemists classify it as a ketohexose, a sugar with six carbon atoms. It differs from sugar alcohols such as xylitol and erythritol. (Mayumi et al., 2021)
Two terms define its role in oral health:
| Term | Meaning | Implication for your product |
|---|---|---|
| Noncariogenic | Does not promote tooth decay | Supports the case for replacing decay-promoting sugars |
| Anti-caries | Helps prevent or limit the decay process | Requires evidence that matches the claimed effect |
FDA regulations include D-tagatose among eligible noncariogenic sweeteners. That recognition supports qualifying food claims. It does not prove that every tagatose product prevents cavities. (21 C.F.R. § 101.80)
Dental Caries, Plaque Bacteria and Tooth Enamel
Dental plaque forms a biofilm: a community of microbes that sticks to teeth. Some bacteria consume sugars and release acids. Repeated acid exposure removes minerals from enamel and can lead to cavities.
Streptococcus mutans contributes to this process, but it does not act alone. Sugar exposure, saliva, fluoride, and the wider microbial community shape caries risk. A fall in one bacterial count does not prove a fall in tooth decay. (Pitts et al., 2017)
For formulation, the whole recipe matters. Replacing sucrose changes the fuel that plaque bacteria receive. Adding tagatose while retaining fermentable sugars leaves those sugars in the product.
Mechanisms Behind Tagatose Anti-Caries Effects
Lab studies explore three main targets: acid production, bacterial growth, and biofilm formation. Results depend on the bacterial strain, sugar mix, concentration, and exposure time.
Lower acid production. Sawada and colleagues studied S. mutans in sucrose-containing media. D-tagatose reduced acid production and the formation of water-insoluble glucans, sticky sugar polymers that help build biofilm. These lab results support further testing of tagatose for controlling tooth decay. They do not establish a clinical dose. (Sawada et al., 2015)
Slower bacterial growth. A 2018 study found that D-tagatose delayed the start of S. mutans growth. The bacteria reached a similar final cell yield. This finding supports growth delay under those conditions, rather than a claim that tagatose kills oral bacteria. (Hasibul et al., 2018)
Less glucan formation. The same study found that tagatose inhibited glucosyltransferase activity. These enzymes help bacteria turn sucrose into glucans. Tagatose reduced biofilm formation in sucrose media, while added fructose removed the growth delay. The surrounding sugars changed the response. (Hasibul et al., 2018)
The evidence does not support a blanket claim that tagatose suppresses every biofilm component. A 2021 study found species-specific effects and increased extracellular polymer production relative to cells under some glucose conditions. The authors proposed sugar-phosphate stress as a possible mechanism; they did not establish it as a human treatment pathway. (Mayumi et al., 2021)
Human Evidence on D-Tagatose and Dental Caries
The clinical evidence covers short-term bacterial counts, saliva pH, and microbial changes. These measures help researchers test a concept. They do not measure the same outcome as fewer new cavities.
| Human study | Design and exposure | Main finding | Commercial interpretation |
|---|---|---|---|
| Nagamine et al., 2020 | 19 healthy volunteers; four-week chewing gum trial | Tagatose plus xylitol reduced salivary S. mutans. Tagatose alone did not reduce it effectively. | The blend merits testing; the trial does not prove tagatose-alone efficacy. |
| Urrutia-Espinosa et al., 2024 | 30 dental students; one-minute rinses with 6.4% tagatose, stevia, or sucrose; follow-up through 48 hours | Tagatose showed lower bacterial counts than sucrose; the corrected review reports no significant difference from stevia. | A small, brief rinse study cannot establish long-term cavity prevention. |
| Zakis et al., 2024 | Pilot trial reporting 65 participants across five groups; 10% sweetener rinses three times per day for two weeks | The tagatose group showed no significant change in microbial composition or saliva pH. | Human exposure did not reproduce a clear oral health benefit in this trial. |
Study sources, including the 2025 correction: Nagamine et al. (2020), Urrutia-Espinosa et al. (2024), and Zakis et al. (2024).
A 2025 systematic review assessed these three trials. Its later correction clarified the null findings from the Zakis study. Read the review and correction together when you build a claims dossier. (Angarita-Davila et al., 2025a, 2025b)
Supporting research adds context. Mayumi and colleagues found an association between higher salivary tagatose and lower plaque scores in 18 people. They did not test whether giving those people tagatose reduced plaque. (Mayumi et al., 2021)
A 2026 mouse study reported less severe caries and changes in oral microbes and inflammatory markers after tagatose exposure. This animal evidence supports further research. It cannot establish a human benefit or serving size. (Zhao et al., 2026)
The clinical gap remains: the studies above do not establish that tagatose alone reduces new cavities over months or years. Keep that gap visible when discussing tagatose cavity prevention.
D-Tagatose vs. Xylitol, Erythritol and Sucrose
Choose a sweetener for the product you plan to make. Separate its role in sugar replacement from any claim about plaque control.
| Sweetener | Ingredient class | Dental relevance | Formulation decision |
|---|---|---|---|
| Sucrose | Sugar | Supplies fuel for acid production and glucan formation | Assess how much the formula can replace |
| D-tagatose | Rare sugar | Noncariogenic; small human trials show mixed results on risk markers | Test the finished formula and any sweetener blend |
| Xylitol | Sugar alcohol | Noncariogenic; human chewing gum research includes bacterial outcomes | Use it as a formulation benchmark, with product-specific evidence |
| Erythritol | Sugar alcohol | Noncariogenic | Compare sensory performance, processing, and cost per serving |
| Sorbitol | Sugar alcohol | Noncariogenic under the FDA framework | Assess the full carbohydrate mix and intended use |
The FDA framework identifies the listed noncariogenic sweeteners. The ADA reviews chewing gum evidence, including xylitol studies. Neither source establishes that tagatose outperforms the alternatives in long-term cavity prevention. (21 C.F.R. § 101.80; American Dental Association, n.d.)
D-Tagatose Applications in Oral Care and Food
Chewing gum offers a starting point. The tagatose–xylitol pilot provides a human research lead for blends. Prototype the blend, measure release during chewing, and compare it with a matched control. Do not transfer the pilot result to a different formula without testing. (Nagamine et al., 2020)
Chewing stimulates saliva. Saliva buffers acids and supplies calcium and phosphate for remineralization. This benefit comes from chewing and saliva flow; it does not prove that tagatose repairs enamel or forms a protective film. (American Dental Association, n.d.)
Mints, lozenges, and chewable tablets need exposure testing. Check dissolution time, serving frequency, and the full carbohydrate profile. Set an acid specification before you add sour flavors.
Toothpaste and mouthwash need separate evidence. You can evaluate tagatose as a sweetening ingredient. Test its compatibility with the active ingredients, preservatives, and flavor system. A food study does not establish rinse or toothpaste performance.
Foods need a whole-formula assessment. Tagatose can form part of a sugar-replacement strategy. Residual sugars, starches, and food acids affect the dental assessment. EFSA’s tooth-mineralization opinion concerns sugar replacement and considers the product’s potential to cause erosion. (EFSA NDA Panel, 2011)
Formulation, Dose and Digestive Tolerance
Human studies have not established an optimal tagatose dose for cavity prevention. A percentage in a lab medium does not translate into grams per serving. Saliva, contact time, and product release change the exposure.
Build the development brief around measurable targets:
| Target | What your team should check |
|---|---|
| Carbohydrate profile | Tagatose content, residual sugars, and other fermentable carbohydrates |
| Oral exposure | Amount per serving, release rate, contact time, and daily use |
| Acidity | Product pH, titratable acidity, and relevant plaque-pH testing |
| Process performance | Dissolution, texture, color, flavor, and stability through shelf life |
| Tolerance | Total intake from the product and other tagatose sources |
| Claim support | A test design that matches the finished product and intended claim |
Higher intakes can cause gas, bloating, or diarrhea. Human tolerance research documents gastrointestinal symptoms with large doses. Do not assume that tagatose causes fewer symptoms than every sugar alcohol. (Buemann et al., 1999)
For children’s products, set an age-specific brief. The small adult oral-health trials do not establish a pediatric dental dose. Apply the same evidence standard to dry-mouth and orthodontic products.
FDA and EFSA: Tagatose Dental Claims
In the United States, 21 CFR § 101.80 permits specified dental-caries claims for qualifying foods with D-tagatose. The rule includes conditions for the claim and the food. When other carbohydrates trigger its testing requirement, the food must not lower plaque pH below 5.7 during consumption or for 30 minutes after consumption.
This food-labeling provision does not grant toothpaste drug approval. Review ingredient status, product category, and claim eligibility as separate questions. (21 C.F.R. § 101.80)
EFSA’s 2011 opinion supports the link between replacing sugars with specified sugar replacers and maintaining tooth mineralization. The opinion does not establish tagatose as a treatment for existing cavities. For an EU launch, check the applicable authorized claim and its conditions of use. (EFSA NDA Panel, 2011)
Bulk D-Tagatose Procurement: Documents Before Price
Ask a D-tagatose supplier for a specification and a recent batch certificate of analysis. Compare assay methods, moisture limits, residual sugars, microbial limits, and contaminant limits. Match each limit to your application and market.
Request samples before you lock the formula. Confirm particle size, packaging, storage conditions, shelf life, lead time, minimum order, and change-control terms. Compare cost per finished serving after the pilot run, not just price per kilogram.
For a BSH Ingredients sourcing discussion, bring your target market, application, annual volume, and required documents. Ask the team to confirm available specifications and supply terms against that brief.
Frequently Asked Questions About D-Tagatose and Dental Caries
Does D-tagatose cause tooth decay?
D-tagatose qualifies as a noncariogenic sweetener under the FDA framework. Other ingredients can affect the finished product’s dental profile. (21 C.F.R. § 101.80)
Can tagatose help prevent cavities?
Replacing decay-promoting sugars supports its use. Lab studies suggest further anti-caries potential, but human trials have not established fewer new cavities from tagatose alone. (Angarita-Davila et al., 2025b)
Can D-tagatose reverse a cavity or remineralize enamel?
The cited studies do not establish either effect. Saliva can support mineral repair in early enamel damage, but that does not make tagatose an enamel-repair ingredient. (American Dental Association, n.d.)
Can Streptococcus mutans use tagatose like sucrose?
Lab research shows different growth and biofilm responses to these sugars. Avoid the broader claim that no oral microbe can metabolize tagatose under any condition. (Hasibul et al., 2018)
Does tagatose remove plaque or tartar?
Lab studies show effects on biofilm formation. They do not establish that a tagatose product removes existing plaque or hardened tartar. (Sawada et al., 2015)
Is tagatose better than xylitol for oral health?
The current human evidence does not establish superiority. One small gum trial found a benefit from the combination, while tagatose alone did not show the same result. (Nagamine et al., 2020)
Can tagatose replace fluoride in toothpaste?
The cited evidence does not support that substitution. The ADA recommends fluoride toothpaste as part of daily oral hygiene; chewing gum serves as an adjunct. (American Dental Association, n.d.)
How much tagatose should an oral care product contain?
Research has not established a universal dental dose. Select a prototype concentration, then test exposure, tolerance, and the intended outcome. (Angarita-Davila et al., 2025b)
Can tagatose help with dry mouth or bad breath?
Chewing gum can stimulate saliva. The cited tagatose trials do not establish treatment benefits for dry mouth or bad breath. (American Dental Association, n.d.; Angarita-Davila et al., 2025b)
Does tagatose cause digestive side effects?
Higher intakes can cause digestive symptoms. Assess total daily exposure when you design the serving size and use instructions. (Buemann et al., 1999)
References
- American Dental Association. (n.d.). Chewing gum. https://www.ada.org/resources/ada-library/oral-health-topics/chewing-gum
- Angarita-Davila, L., Fuentes-Barría, H., Rojas-Gómez, D., Aguilera-Eguía, R., Alarcón-Rivera, M., & Guzmán-Muñoz, E. (2025a). Correction: Angarita-Davila et al. Effects of D-tagatose on cariogenic risk: A systematic review of randomized clinical trials. Nutrients 2025, 17, 293. Nutrients, 17(17), Article 2807. https://doi.org/10.3390/nu17172807
- Angarita-Davila, L., Fuentes-Barría, H., Rojas-Gómez, D., Aguilera-Eguía, R., Alarcón-Rivera, M., & Guzmán-Muñoz, E. (2025b). Effects of D-tagatose on cariogenic risk: A systematic review of randomized clinical trials. Nutrients, 17(2), Article 293. https://doi.org/10.3390/nu17020293
- Buemann, B., Toubro, S., & Astrup, A. (1999). Human gastrointestinal tolerance to D-tagatose. Regulatory Toxicology and Pharmacology, 29(2, Part 2), S71–S77. https://doi.org/10.1006/rtph.1998.1265
- EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). (2011). Scientific opinion on the substantiation of health claims related to the sugar replacers xylitol, sorbitol, mannitol, maltitol, lactitol, isomalt, erythritol, D-tagatose, isomaltulose, sucralose and polydextrose and maintenance of tooth mineralisation by decreasing tooth demineralisation (ID 463, 464, 563, 618, 647, 1182, 1591, 2907, 2921, 4300), and reduction of post-prandial glycaemic responses (ID 617, 619, 669, 1590, 1762, 2903, 2908, 2920) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal, 9(4), Article 2076. https://doi.org/10.2903/j.efsa.2011.2076
- Hasibul, K., Nakayama-Imaohji, H., Hashimoto, M., Yamasaki, H., Ogawa, T., Waki, J., Tada, A., Yoneda, S., Tokuda, M., Miyake, M., & Kuwahara, T. (2018). D-tagatose inhibits the growth and biofilm formation of Streptococcus mutans. Molecular Medicine Reports, 17(1), 843–851. https://doi.org/10.3892/mmr.2017.8017
- Health claims: Dietary noncariogenic carbohydrate sweeteners and dental caries, 21 C.F.R. § 101.80 (2026). https://www.law.cornell.edu/cfr/text/21/101.80
- Mayumi, S., Kuboniwa, M., Sakanaka, A., Hashino, E., Ishikawa, A., Ijima, Y., & Amano, A. (2021). Potential of prebiotic D-tagatose for prevention of oral disease. Frontiers in Cellular and Infection Microbiology, 11, Article 767944. https://doi.org/10.3389/fcimb.2021.767944
- Nagamine, Y., Hasibul, K., Ogawa, T., Tada, A., Kamitori, K., Hossain, A., Yamaguchi, F., Tokuda, M., Kuwahara, T., & Miyake, M. (2020). D-tagatose effectively reduces the number of Streptococcus mutans and oral bacteria in healthy adult subjects: A chewing gum pilot study and randomized clinical trial. Acta Medica Okayama, 74(4), 307–317. https://doi.org/10.18926/AMO/60369
- Pitts, N. B., Zero, D. T., Marsh, P. D., Ekstrand, K., Weintraub, J. A., Ramos-Gomez, F., Tagami, J., Twetman, S., Tsakos, G., & Ismail, A. (2017). Dental caries. Nature Reviews Disease Primers, 3, Article 17030. https://doi.org/10.1038/nrdp.2017.30
- Sawada, D., Ogawa, T., Miyake, M., Hasui, Y., Yamaguchi, F., Izumori, K., & Tokuda, M. (2015). Potent inhibitory effects of D-tagatose on the acid production and water-insoluble glucan synthesis of Streptococcus mutans GS5 in the presence of sucrose. Acta Medica Okayama, 69(2), 105–111. https://doi.org/10.18926/AMO/53339
- Urrutia-Espinosa, M., Concha-Fuentealba, F., Fuentes-Barría, H., Angarita Dávila, L. C., Carrasco Hernández, M. E., Aguilera-Eguía, R., Alarcón Rivera, M., & López Soto, O. P. (2024). Effects of D-tagatose, stevia and sucrose on pH and oral bacterial activity in dentistry students: A randomized controlled trial. Nutrición Hospitalaria, 41(5), 1091–1097. https://doi.org/10.20960/nh.05253
- Zakis, D. R., Brandt, B. W., van der Waal, S. V., Keijser, B. J. F., Crielaard, W., van der Plas, D. W. K., Volgenant, C. M. C., & Zaura, E. (2024). The effect of different sweeteners on the oral microbiome: A randomized clinical exploratory pilot study. Journal of Oral Microbiology, 16(1), Article 2369350. https://doi.org/10.1080/20002297.2024.2369350
- Zhao, L., Wang, H., Miao, C., Chen, Q., Wang, W., Ma, W., Zhang, W., Wen, Q., Wang, R., Zhang, W., & Xiong, W. (2026). Tagatose attenuates Streptococcus mutans-induced dental caries by modulating oral microbiota and inflammatory responses in mice. BMC Microbiology, 26, Article 191. https://doi.org/10.1186/s12866-026-04734-0
